Browsing Tag
skin cancer immunotherapy
2 posts
Could intratumoral peptide immunotherapy alter first-line thinking in basal cell carcinoma?
Could VP-315 reshape first-line basal cell carcinoma treatment? Read the executive analysis on strategy, competition, and commercial risks.
Sun Pharmaceutical faces regulatory pause as EMA application for melanoma drug withdrawn
Sun Pharmaceutical’s EU partner Philogen has withdrawn its EMA application for Nidlegy, delaying regulatory progress in melanoma care. Read what’s next.